IRADIMED CORPORATION Reports First Quarter 2026 Financial Results
Iradimed reported Q1 2026 revenue of $22.0 million, up 13% year-over-year, driven by double-digit growth in its MRI-compatible device portfolio. GAAP diluted EPS rose 22% to $0.45, while operating income increased 33% to $7.2 million, supported by disciplined expense management.
Key figures
- Eps
- 0.45
- Revenue
- $22.0 million
- Guidance
- FY26 revenue $91.0M-$96.0M, reaffirmed
- Revenue Yoy
- 13%
- Operating income
- $7.2 million
- Dividend per share
- $0.20
- Cash flow from operations
- $8.3 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.